title: [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
abstract: OBJECTIVE
  The purpose of this study was to assess the safety of TS-1 when used as adjuvant chemotherapy after surgical resection of advanced stomach cancer.
  
  
  METHODS
  The subjects were 20 patients with stage III or IV, curability B resected gastric cancer.
  
  
  METHODS
  The methods consisted of analysis of background factors, assessment of the administration and dosage of TS-1, and associations with adverse reactions.
  
  
  RESULTS
  Mean age was 62.8 years, and the histological type was differentiated in 7 cases and undifferentiated in 13 cases. There were 4 stage IIIA cases, 10 stage IIIB cases, and 6 stage IV cases, and the extent of gastric resection consisted of gastrectomy in 8 cases and total gastrectomy in 12 cases. TS-1 administration was started an average of 57 days postoperatively. The dosage regimen was 4 weeks on and 2 weeks off in 10 cases, and different regimens were used in the other 10 cases. The dose of TS-1 was the recommended dose in 9 cases and a reduced dose in 11 cases, and the mean number of courses was 2.8. Adverse reactions occurred in a total of 14 cases. Digestive system toxicity developed in 5 cases and hematological toxicity in 12. No grade 3 or 4 toxicity was observed. Treatment could be continued in 18 cases. The occurrence of adverse reactions tended to be concentrated immediately after administration of TS-1.
  
  
  CONCLUSIONS
  TS-1 was safely used as adjuvant chemotherapy after resection of advanced stomach cancer.
authors.affiliation: Dept. of Surgery, Saiseikai Suita Hospital.
authors.forename: Akinori
authors.initials: A
authors.lastname: Hara
authors.forename: Takaya
authors.initials: T
authors.lastname: Tokuhara
authors.forename: Yuko
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Izumi
authors.forename: Shinji
authors.initials: S
authors.lastname: Iwamoto
authors.forename: Kazunari
authors.initials: K
authors.lastname: Satake
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005240:Feasibility Studies; D005743:Gastrectomy; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011184:Postoperative Period; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid